my assumption would be company would be picked apart and sold for scrap with only people having critical product knowledge retained and TP and EVPs getting the typical golden parachutes.
6 replies (most recent on top)
@hz rather than financial reason, it could be dangerous to buy a culturally cancerous organisation. If anyone really buying BD, they need to kick out most of the ‘leaders’ till VP.
@d1 unfortunately debt to equity ratio is low but BD is a behemoth and such a mess. I don't think we are an acquisition target. There's no vision with the portfolio where we could be an acquisition target. Until 4 years back, BD was all in Life Sciences and we just divested two BUs. I think it is more likely that we divest some more business units.
@e8 Legacy Bard had a very compliant quality system. Making implantable medical devices. Strong leaders pushed BD to strengthen quality and compliance. Over time many BARD leaders have retired or left the organization.
Sell the legacy BARd segments!!! Oh wait, can’t do that as they are the only ones making money for BD
The medical device industry has experienced consistent growth year over year, yet BDX stock has grown < 1% over the past 5 years. This poor performance is due to weak and naive leadership that learns and then obsesses about basic principles like kaizen (which has been around for decades and should have always been a basic way of working). Last year leadership came to the amazing revelation that they need to focus on marketing and revenue growth! This of course only happened after the stock plummeted. lol. The company has a low level of debt relative to equity which would make it ripe for acquisition but with this place, nothing would surprise me. It all depends on the BOD and how much longer they’re willing to tolerate the CEO and the company’s underperformance.